


Technology Appraisal Committee C Interests Register Topic: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [ID1648]

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Michael Chambers	Committee member	Direct financial	Michael has recently participated in some podcasts on Health Technology Assessment funded by Boehringer Ingelheim (BI), but these did not involve consideration of any BI products.	15.12.2022 & 09.03.2023	N/A	It was agreed that his declaration would not prevent Michael from participating in discussions on this appraisal.
Professor Matthew Stevenson	Committee member	Direct financial	Professor Stevenson has received funding from AstraZeneca but not in relation to this appraisal.	14.02.2023 & 09.03.2023	N/A	It was agreed that his declaration would not prevent Professor Stevenson from participating in discussions on this appraisal
Dr Lisa Anderson	Clinical expert	Indirect financial	AstraZeneca signed a 2-year Joint Working agreement with the Endocrinology and Cardiology departments at St George's Hospital in September 2020 to fund a weekly Cardiometabolic clinic	20.09.2022	N/A	It was agreed her declaration would not prevent Dr Anderson from providing expert advice to the committee



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			for 2 years, she is not directly involved in the delivery of this service but as Heart Failure lead and is now working with the CCG to ensure long-term NHS funding for the clinic.			
Dr Andrew Ludman	Clinical expert	Direct financial & non-financial	Dr Ludman has received fees from AstraZeneca for teaching primary and secondary care health professionals around SGLT2i and dapagliflozin, he is also local principal investigator for the DAPA-MI clinical trial which is recruiting patients after a heart attack and randomising to placebo v dapagliflozin.	29.07.2022	N/A	It was agreed that his declaration would not prevent Dr Ludman from providing expert advice to the committee